SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer

Endocrine-Related Cancer

Volumn 21, Issue 2, 2014, Pages 175-187

  Hoefer, Julia ^a   Kern, Johann ^b   Ofer, Philipp ^a   Eder, Iris E ^a   Schäfer, Georg ^a   Dietrich, Dimo ^c   Kristiansen, Glen ^c   Geley, Stephan ^a   Rainer, Johannes ^a   Gunsilius, Eberhard ^b   Klocker, Helmut ^a   Culig, Zoran ^a   Puhr, Martin ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Tumor Biology and Angiogenesis Laboratory   (Austria)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Androgen; Proliferation; Prostate cancer; SOCS2; Survival

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; DOXYCYCLINE; SHORT HAIRPIN RNA; SUPPRESSOR OF CYTOKINE SIGNALING 2;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CHORIOALLANTOIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; GENE SILENCING; GLEASON SCORE; GROWTH REGULATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR XENOGRAFT; UPREGULATION;

ANDROGEN; PROLIFERATION; PROSTATE CANCER; SOCS2; SURVIVAL;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR BURDEN;

EID: 84899864297     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0446     Document Type: Article

References (69)

1. Arany I, Muldrow M & Tyring SK 2001 The endogenous interferon system in anal squamous epithelial lesions with different grades from HIV-positive individuals. International Journal of STD & AIDS 12 229-233. (doi:10.1258/0956462011922977)
2. Armstrong PB, Quigley JP & Sidebottom E 1982 Transepithelial invasion and intramesenchymal infiltration of the chick embryo chorioallantois by tumor cell lines. Cancer Research 42 1826-1837.
3. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A et al. 2006 Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. American Journal of Pathology 169 2199-2208. (doi:10.2353/ajpath.2006.060171)
4. Buchanan G, Irvine RA, Coetzee GA & Tilley WD 2001 Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Reviews 20 207-223. (doi:10.1023/A:1015531326689)
5. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L & Pollak M 2009 Insulin receptor expression by human prostate cancers. Prostate 69 33-40. (doi:10.1002/pros.20852)
6. Croker BA, Kiu H & Nicholson SE 2008 SOCS regulation of the JAK/STAT signalling pathway. Seminars in Cell & Developmental Biology 19 414-422. (doi:10.1016/j.semcdb.2008.07.010)
7. Culig Z 2011 Cytokine disbalance in common human cancers. Biochimica et Biophysica Acta 1813 308-314. (doi:10.1016/j.bbamcr.2010.12.010)
8. Culig Z 2013 Suppressors of cytokine signalling-3 and-1 in human carcinogenesis. Frontiers in Bioscience 5 277-283. (doi:10.2741/S372)
9. Culig Z & Puhr M 2012 Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Molecular and Cellular Endocrinology 360 52-58. (doi:10.1016/j.mce.2011.05.033)
10. Deryugina EI & Quigley JP 2008 Chapter 2. Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules. Methods in Enzymology 444 21-41.
11. Detre S, Saclani Jotti G & Dowsett M 1995 A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. Journal of Clinical Pathology 48 876-878. (doi:10.1136/jcp.48.9.876)
12. Dey BR, Spence SL, Nissley P & Furlanetto RW 1998 Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. Journal of Biological Chemistry 273 24095-24101. (doi:10.1074/jbc.273.37.24095)
13. Dietrich D, Hasinger O, Liebenberg V, Field JK, Kristiansen G & Soltermann A 2012 DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagnostic Molecular Pathology 21 93-104. (doi:10.1097/PDM.0b013e318240503b)
14. Dutt SS & Gao AC 2009 Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncology 5 1403-1413. (doi:10.2217/fon.09. 117)
15. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H et al. 1997 A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387 921-924. (doi:10.1038/43213)
16. Favre H, Benhamou A, Finidori J, Kelly PA & Edery M 1999 Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Letters 453 63-66. (doi:10.1016/S0014-5793(99)00681-X)
17. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J et al. 2004 Bioconductor: open software development for computational biology and bioinformatics. Genome Biology 5 R80. (doi:10.1186/gb-2004-5-10-r80)
18. Goffin V, Hoang DT, Bogorad RL & Nevalainen MT 2011 Prolactin regulation of the prostate gland: a female player in a male game. Nature Reviews. Urology 8 597-607. (doi:10.1038/nrurol.2011.143)
19. Greenhalgh CJ, Metcalf D, Thaus AL, Corbin JE, Uren R, Morgan PO, Fabri LJ, Zhang JG, Martin HM, Willson TA et al. 2002 Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. Journal of Biological Chemistry 277 40181-40184. (doi:10.1074/jbc.C200450200)
20. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G & Schaper F 2003 Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal 374 1-20. (doi:10.1042/BJ20030407)
21. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J & Jenster G 2006 Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Research 66 5012-5020. (doi:10.1158/0008-5472.CAN-05-3082)
22. Hoefer J, Schafer G, Klocker H, Erb HH, Mills IG, Hengst L, Puhr M & Culig Z 2012 PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. American Journal of Pathology 180 2097-2107. (doi:10.1016/j.ajpath.2012.01.026)
23. Iglesias-Gato D, Chuan YC, Wikstrom P, Augsten S, Jiang N, Niu Y, Seipel A, Danneman D, Vermeij M, Fernandez-Perez L et al. 2013 SOCS2 mediates the crosstalk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis [in press].
24. Jemal A, Siegel R, Xu J & Ward E 2011 Cancer statistics 2010. CA: A Cancer Journal for Clinicians 60 277-300. (doi:10.3322/caac.20073)
25. Kamura T, Sato S, Haque D, Liu L, Kaelin WG Jr, Conaway RC & Conaway JW 1998 The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes and Development 12 3872-3881. (doi:10.1101/gad.12.24.3872)
26. Kamura T, Maenaka K, Kotoshiba S, Matsumoto M, Kohda D, Conaway RC, Conaway JW & Nakayama KI 2004 VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes and Development 18 3055-3065. (doi:10.1101/gad.1252404)
27. Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, Klocker H, Wasylyk B, Voller M, Aalders T et al. 2006 hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Research 66 3531-3540. (doi:10.1158/0008-5472.CAN-05-2183)
28. Kunzi-Rapp K, Genze F, Kufer R, Reich E, Hautmann RE & Gschwend JE 2001 Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. Journal of Urology 166 1502-1507. (doi:10.1016/S0022-5347(05)65820-X)
29. Larsen L & Ropke C 2002 Suppressors of cytokine signalling: SOCS. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 110 833-844. (doi:10.1034/j.1600-0463.2002.1101201.x)
30. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME & Nelson CC 2008 Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 68 6407-6415. (doi:10.1158/0008-5472.CAN-07-5997)
31. Lonergan PE & Tindall DJ 2011 Androgen receptor signaling in prostate cancer development and progression. Journal of Carcinogenesis 10 20. (doi:10.4103/1477-3163.83937)
32. Martowicz A, Rainer J, Lelong J, Spizzo G, Gastl G & Untergasser G 2013 EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth. Molecular Cancer 12 56. (doi:10.1186/1476-4598-12-56)
33. Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, Hilton DJ & Alexander WS 2000 Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405 1069-1073. (doi:10.1038/35016611)
34. Monti S, Proietti-Pannunzi L, Sciarra A, Lolli F, Falasca P, Poggi M, Celi FS & Toscano V 2007 The IGF axis in prostate cancer. Current Pharmaceutical Design 13 719-727. (doi:10.2174/138161207780249128)
35. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K et al. 1997 Structure and function of a new STAT-induced STAT inhibitor. Nature 387 924-929. (doi:10.1038/43219)
36. Nakonechnaya AO, Jefferson HS, Chen X & Shewchuk BM 2013 Differential effects of exogenous and autocrine growth hormone on LNCaP prostate cancer cell proliferation and survival. Journal of Cellular Biochemistry 114 1322-1335. (doi:10.1002/jcb.24473)
37. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A & Culig Z 2007 Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocrine-Related Cancer 14 1007-1019. (doi:10.1677/ERC-07-0172)
38. Neuwirt H, Puhr M, Santer FR, Susani M, Doppler W, Marcias G, Rauch V, Brugger M, Hobisch A, Kenner L et al. 2009 Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. American Journal of Pathology 174 1921-1930. (doi:10.2353/ajpath.2009.080751)
39. Pezet A, Favre H, Kelly PA & Edery M 1999 Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. Journal of Biological Chemistry 274 24497-24502. (doi:10.1074/jbc.274.35.24497)
40. Pfeiffer MJ, Mulders PF & Schalken JA 2010 An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. Prostate 70 1524-1532. (doi:10.1002/pros.21187)
41. Pierconti F, Martini M, Pinto F, Cenci T, Capodimonti S, Calarco A, Bassi PF & Larocca LM 2011 Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate 71 318-325. (doi:10.1002/pros.21245)
42. Piessevaux J, Lavens D, Montoye T, Wauman J, Catteeuw D, Vandekerckhove J, Belsham D, Peelman F & Tavernier J 2006 Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. Journal of Biological Chemistry 281 32953-32966. (doi:10.1074/jbc.M600776200)
43. Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L & Culig Z 2009 Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Research 69 7375-7384. (doi:10.1158/0008-5472.CAN-09- 0806)
44. Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A & Culig Z 2010 SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. Endocrine-Related Cancer 17 525-538. (doi:10.1677/ERC-10-0007)
45. Qiu X, Zheng J, Guo X, Gao X, Liu H, Tu Y & Zhang Y 2013 Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. Molecular and Cellular Biochemistry 378 99-106. (doi:10.1007/s11010-013-1599-5)
46. Rainer J, Lelong J, Bindreither D, Mantinger C, Ploner C, Geley S & Kofler R 2012 Research resource: transcriptional response to glucocorticoids in childhood acute lymphoblastic leukemia. Molecular Endocinology 26 178-193. (doi:10.1210/me.2011-1213)
47. Rico-Bautista E, Flores-Morales A & Fernandez-Perez L 2006 Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine & Growth Factor Reviews 17 431-439. (doi:10.1016/j.cytogfr. 2006.09.008)
48. Roberts CT Jr 2004 IGF-1 and prostate cancer. Novartis Foundation Symposium 262 193-199 discussion 199-204, 265-198.
49. Rui L, Yuan M, Frantz D, Shoelson S & White MF 2002 SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. Journal of Biological Chemistry 277 42394-42398. (doi:10.1074/jbc.C200444200)
50. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, Rottapel R, Yamaoka S & Lu KP 2003 Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Molecular Cell 12 1413-1426. (doi:10.1016/S1097-2765(03)00490-8)
51. Sadowski CL, Choi TS, Le M, Wheeler TT, Wang LH & Sadowski HB 2001 Insulin induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 skeletal muscle cells is mediated by Stat5*. Journal of Biological Chemistry 276 20703-20710. (doi:10.1074/jbc.M101014200)
52. Saw CL, Heng PW & Liew CV 2008 Chick chorioallantoic membrane as an in situ biological membrane for pharmaceutical formulation development: a review. Drug Development and Industrial Pharmacy 34 1168-1177. (doi:10.1080/03639040801974295)
53. Schultheis B, Carapeti-Marootian M, Hochhaus A, Weisser A, Goldman JM & Melo JV 2002 Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 99 1766-1775. (doi:10.1182/blood.V99.5.1766)
54. Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY & Johnson FM 2011 STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clinical Cancer Research 18 127-139. (doi:10.1158/1078-0432.CCR-11-1889)
55. Siewert E, Muller-Esterl W, Starr R, Heinrich PC & Schaper F 1999 Different protein turnover of interleukin-6-type cytokine signalling components. European Journal of Biochemistry 265 251-257. (doi:10.1046/j.1432-1327.1999. 00719.x)
56. Sigl R, Wandke C, Rauch V, Kirk J, Hunt T & Geley S 2009 Loss of the mammalian APC/C activator FZR1 shortens G1 and lengthens S phase but has little effect on exit from mitosis. Journal of Cell Science 122 4208-4217. (doi:10.1242/jcs.054197)
57. Singh N, Hussain S, Bharadwaj M, Kakkar N, Singh SK & Sobti RC 2012 Overexpression of signal transducer and activator of transcription (STAT-3 and STAT-5) transcription factors and alteration of suppressor of cytokine signaling (SOCS-1) protein in prostate cancer. Journal of Receptors and Signal Transduction Research 32 321-327. (doi:10.3109/10799893.2012.733885)
58. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA et al. 1997 A family of cytokine-inducible inhibitors of signalling. Nature 387 917-921. (doi:10.1038/43206)
59. Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG & Visvader JE 2004 Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23 7726-7733. (doi:10.1038/sj.onc.1207787)
60. Taizi M, Deutsch VR, Leitner A, Ohana A & Goldstein RS 2006 A novel and rapid in vivo system for testing therapeutics on human leukemias. Experimental Hematology 34 1698-1708. (doi:10.1016/j.exphem. 2006.07.005)
61. Tan SH & Nevalainen MT 2008 Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocrine-Related Cancer 15 367-390. (doi:10.1677/ERC-08-0013)
62. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z et al. 2008 Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Research 68 236-248. (doi:10.1158/0008-5472.CAN-07-2972)
63. Tannahill GM, Elliott J, Barry AC, Hibbert L, Cacalano NA & Johnston JA 2005 SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Molecular and Cellular Biology 25 9115-9126. (doi:10.1128/MCB.25.20.9115-9126.2005)
64. Tavaszi J & Budai P 2006 Toxicity study of agrochemicals on chorioallan-toic membrane of the egg. Communications in Agricultural and Applied Biological Sciences 71 101-105.
65. Trengove MC & Ward AC 2013 SOCS proteins in development and disease. American Journal of Clinical and Experimental Immunology 2 1-29.
66. Vidal OM, Merino R, Rico-Bautista E, Fernandez-Perez L, Chia DJ, Woelfle J, Ono M, Lenhard B, Norstedt G, Rotwein P et al. 2007 In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Molecular Endocinology 21 293-311. (doi:10.1210/me.2006-0096)
67. Wang L, Zhang Z, Zhang R, Hafner MS, Wong HK, Jiao Z & Chopp M 2004 Erythropoietin up-regulates SOCS2 in neuronal progenitor cells derived from SVZ of adult rat. Neuroreport 15 1225-1229. (doi:10.1097/01.wnr.0000127636.15181.c1)
68. Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S & Knuutila S 2002 Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 21 5804-5813. (doi:10.1038/sj.onc.1205726)
69. Zhu JG, Dai QS, Han ZD, He HC, Mo RJ, Chen G, Chen YF, Wu YD, Yang SB, Jiang FN et al. 2013 Expression of SOCSs in human prostate cancer and their association in prognosis. Molecular and Cellular Biochemistry 381 51-59. (doi:10.1007/s11010-013-1687-6)